文献速递神经肿瘤

胶质母细胞瘤细胞内在与外在治疗靶点:通过肿瘤微环境调控与精准医学克服耐药

Cell-Intrinsic and Cell-Extrinsic Therapeutic Targets in Glioblastoma: Overcoming Resistance Through Tumor Microenvironment Modulation and Precision Medicine.
PubMed 文献 · World Neurosurg · 2025-06-04

结论指出复发胶质母细胞瘤向间质表型转变驱动耐药,靶向间质转化通路(如AP-1调控)及逆转CD8+ T细胞耗竭和Treg介导的免疫抑制可能改善治疗。

要点

  • 表型可塑性而非DNA突变是胶质母细胞瘤复发的基礎。
  • 复发胶质母细胞瘤向间质表型转变驱动治疗耐药。
  • 靶向间质转化通路及逆转免疫抑制可增强疗效。

核心结论

  • 复发胶质母细胞瘤向间质表型转变驱动耐药,靶向间质转化通路如AP-1调控可能改善治疗。
  • 逆转CD8+ T细胞耗竭和调节性T细胞介导的免疫抑制可增强免疫治疗。
  • 破坏肿瘤微环境介导的信号传导是克服耐药的有前景策略。

研究设计与样本

  • 纳入观察性研究、临床试验、meta分析和综述进行分析。

主要发现

  • 表型可塑性而非DNA突变是胶质母细胞瘤复发的基础,使肿瘤细胞逃避靶向治疗。
  • 单细胞谱系追踪显示胶质母细胞瘤细胞通过与星形胶质细胞、小胶质细胞和免疫细胞的复杂信号在肿瘤微环境中动态适应。
  • 复发胶质母细胞瘤显示T细胞浸润增加,但以耗竭CD8+ T细胞和调节性T细胞为主,促进免疫逃逸。

临床怎么用

  • 靶向间质转化通路(如AP-1调控)可能改善复发胶质母细胞瘤治疗。
  • 逆转CD8+ T细胞耗竭和调节性T细胞介导的免疫抑制可增强免疫治疗。
  • 破坏肿瘤微环境介导的信号传导可作为克服耐药的策略。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Glioblastoma (GBM) is an aggressive primary brain tumor with poor prognosis despite multimodal treatment. While prior research focused on tumor cell evolution, growing evidence highlights the tumor microenvironment (TME) as a key driver of therapeutic resistance and disease progression. Understanding GBM-TME interactions is crucial for identifying novel therapeutic targets. METHODS: A comprehensive literature search was conducted in PubMed, Embase, and Web of Science for English-language studies up to December 2024. Relevant observational studies, clinical trials, meta-analyses, and reviews were analyzed to evaluate cell-intrinsic and cell-extrinsic mechanisms driving GBM progression and treatment resistance. RESULTS: Emerging evidence suggests that phenotypic plasticity, rather than DNA mutations, underlies GBM recurrence, allowing tumor cells to evade targeted therapies. Single-cell lineage tracking reveals that GBM cells dynamically adapt within the TME through complex signaling with astrocytes, microglia, and immune cells, fostering an immunosuppressive microenvironment. Recurrent GBM shows increased T-cell infiltration but is dominated by exhausted CD8+ T cells and regulatory T cells, promoting immune evasion. Disrupting these tumor-supportive interactions offers a therapeutic opportunity. CONCLUSIONS: Recurrent GBM shifts toward a mesenchymal phenotype, driving resistance. Targeting mesenchymal transition pathways, such as activator protein 1 modulation, may improve therapy. Additionally, reversing CD8+ T-cell exhaustion and regulatory T cell-mediated immunosuppression could enhance immunotherapy. Disrupting TME-mediated signaling represents a promising strategy to overcome resistance. This review highlights both cell-intrinsic and cell-extrinsic therapeutic targets and insights from single-cell multiomics for future GBM treatments.

来源:World Neurosurg,查看原文。版权归原作者所有。

引用

  1. Shah S, Lucke-Wold B. Cell-Intrinsic and Cell-Extrinsic Therapeutic Targets in Glioblastoma: Overcoming Resistance Through Tumor Microenvironment Modulation and Precision Medicine. World Neurosurg. 2025. PMID: 40480545. doi:10.1016/j.wneu.2025.124142

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。